5 completed, 3 not yet recruiting, 2 recruiting, 1 active not recruiting. 4 Phase 1, 3 Not applicable, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Not yet recruiting 2 |
| Not applicable | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Malaria Infection: new trials by email Literature Review of Malaria Infection trials Research Report on Malaria Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Humanitarian Evaluation of Spatial Emanators for Malaria Control Guardian™ long-lasting spatial emanators - Malaria Infection | Phase 4 | Not yet recruiting | The Mentor Initiative | 32584 | 2026-10-26 | 2026-10-21 |
| Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda MMV371, Placebo for MMV371 - Malaria (Plasmodium Falciparum), Malaria Falciparum | Phase 1 | Not yet recruiting | Medicines for Malaria Venture | 80 | 2026-09-01 | 2026-04-23 |
| Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP NF54/iGP3 - Malaria Falciparum, Malaria Infection | Phase 1 | Not yet recruiting | University of Melbourne | 2 | 2025-07-01 | 2025-03-18 |
| Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad "Synchronised" arm (intervention) - Malaria Infection, Malaria Vaccines | Phase 4 | Recruiting | Epicentre | 70000 | 2025-06-16 | 2026-04-15 |
| IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding Dihydroartemisinin piperaquine, Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis, Long-lasting Insecticidal Net - Malaria Infection, Malaria Falciparum | Not applicable | Active not recruiting | University of North Carolina, Chapel Hill | 36000 | 2025-03-12 | 2026-09-22 |
| Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection | Phase 1 | Completed | Sanaria Inc. | 75 | 2025-03-04 | 2026-04-16 |
| Burden of Schistosomiasis and Soil-transmitted Helminth Infections in Schoolchildren in Banfora, Burkina Faso Dihydroartemisin-piperaquine - Schistosomiasis in Children, Soil Transmitted Helminth (STH) Infections | Completed | Centre MURAZ/Institut National de Santé Publique | 300 | 2024-11-11 | 2025-05-15 | |
| Diagnostic Access to Self-Care and Health Services in Low and Middle Income Countries (DASH) - Phase II Home-based rapid testing, Community health worker rapid testing - Malaria Infection, Pregnancy | Not applicable | Unknown | University of Washington | 2250 | 2024-10-01 | 2024-09-19 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
| Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana DHAP, Single low dose PQ - Malaria Asymptomatic Parasitaemia, Malaria Falciparum | Not applicable | Recruiting | Noguchi Memorial Institute for Medical Research | 9000 | 2023-11-01 | 2026-02-05 |
| Malaria Vaccine for Children in Mali AMA1-C1/Alhydrogel plus CPG 7909 - Malaria, Malaria Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2008-08-11 | 2017-07-02 |
| Malaria Incidence in Infants in Bancoumana, Mali Malaria Infection, Malaria Incidence | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 600 | 2007-07-24 | 2017-07-02 |
Malaria (9) · Malaria, Falciparum (7) · Anemia (2) · Asymptomatic Infections (1) · Child Nutrition Disorders (1) · Diabetes Mellitus (1) · Hypertension (1) · Infections (1)
Infections (10) · Mosquito-Borne Diseases (10) · Parasitic Diseases (10) · Protozoan Infections (10) · Vector Borne Diseases (10) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Nutritional and Metabolic Diseases (2) · Asymptomatic Diseases (1) · Cardiovascular Diseases (1) · Disease Attributes (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Malaria (1) · Metabolic Diseases (1)
Methods (1) · ProMune (1) · Saline Solution (1) · Single Person (1) · atovaquone, proguanil drug combination (1) · pyronaridine (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Centre MURAZ/Institut National de Santé Publique (1) · Epicentre (1) · Medicines for Malaria Venture (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Noguchi Memorial Institute for Medical Research (1) · Sanaria Inc. (1) · The Mentor Initiative (1) · University of Melbourne (1) · University of North Carolina, Chapel Hill (1) · University of Washington (1)
Burkina Faso (3) · Kenya (2) · Zambia (2) · Australia (1) · Chad (1) · Ghana (1) · Mali (1) · Rwanda (1) · South Africa (1) · South Sudan (1) · The Gambia (1) · Uganda (1) · United States (1)
James McCarthy (1) · Jean-Claude Sumanyi, PMhH (1) · Ndong Ignatius Cheng, PhD (1) · Paul Drain, MD, MPH (1) · Richard J Allan, PhD, OBE (1) · Ross Boyce, MD, M.Sc. (1)
R01AI173558 (1)